MMP2 and glomerulosclerosis: BM-MSC-eGFP (× 2) treatment significantly reduced the HS-induced TNF-α levels (Figure S3 [Supplementary File]), interstitial kidney fibrosis (Fig. 5L), TGF-β1(Fig. 6E) and pSmad2 (Fig. 6F) levels, attenuated the HS-induced glomerulosclerosis to levels that were not different to that measured in NDW-fed controls (Fig. 5M), and increased MMP-2 activity (Fig. 6C and H) after 2-weeks of treatment.